PharmaCielo Ltd. (PCLOF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $7.04M is the value of all shares combined. Beta 0.16: the stock has moved about 84% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPharmaCielo Ltd. (PCLOF) trades at $0.03744. PharmaCielo Ltd. cultivates, processes, and supplies medicinal-grade cannabis extracts and related products. Market cap: $7.04M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PCLOF: PCLOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PCLOF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
PCLOF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
PharmaCielo Ltd. (PCLOF) Healthcare & Pipeline Overview
PharmaCielo Ltd. focuses on the cultivation, processing, and supply of medicinal-grade cannabis extracts and related products, including telemedicine software. The company operates primarily in Canada and Colombia, serving health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, navigating a competitive landscape within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for PCLOF?
PharmaCielo Ltd. presents a speculative investment opportunity within the medicinal cannabis sector. With a market capitalization of $7.04M and a negative P/E ratio of -2.68, the company's valuation reflects its current challenges in achieving profitability. A key value driver is the potential expansion of its medicinal cannabis product line and penetration into new geographic markets. The company's strategic alliance with AssuredTrans Inc. could improve its supply chain efficiencies and market access. However, the company's negative profit margin of -174.4% raises concerns about its financial sustainability. The company's beta of 0.16 suggests lower volatility compared to the overall market. Investors should closely monitor PharmaCielo's ability to improve its financial performance and capitalize on growth opportunities within the medicinal cannabis market. The ongoing development and commercialization of its telemedicine software may also provide additional revenue streams.
Based on FMP financials and quantitative analysis
PCLOF Key Highlights
Market Cap of $7.04M indicates a micro-cap company with high growth potential but also significant risk.
- P/E Ratio of -2.68 reflects the company's current lack of profitability, requiring further investigation into its earnings potential.
- Profit Margin of -174.4% signals significant operational inefficiencies or high costs, necessitating a turnaround strategy.
- Gross Margin of 29.0% suggests some ability to generate profit from sales, but needs improvement to achieve overall profitability.
- Strategic alliance with AssuredTrans Inc. aims to enhance supply chain and distribution capabilities, potentially improving market access.
Who Are PCLOF's Competitors?
PCLOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVTBF Avant Brands Inc. | $0.42 | -4.08% | $6.35M | — |
| BBRRF Blueberries Medical Corp. | $0.01 | +0.00% | $5.94M | — |
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are PCLOF's Key Strengths?
Focus on medicinal-grade cannabis.
- Strategic alliance with AssuredTrans Inc.
- Telemedicine software offering.
- Operations in Canada and Colombia.
What Are PCLOF's Weaknesses?
Negative profit margin.
- Limited market share.
- Dependence on regulatory approvals.
- Limited brand recognition.
What Could Drive PCLOF Stock Higher?
Potential regulatory approvals for cannabis-based therapies in new markets.
- Expansion of the company's telemedicine platform to reach a wider patient base.
- Development and commercialization of proprietary cannabis formulations.
- Strategic partnerships or acquisitions to expand product portfolio and geographic reach.
- Efforts to improve operational efficiencies and reduce costs to achieve profitability.
What Are the Key Risks for PCLOF?
Financial-distress signal — its Altman Z-Score of -25.27 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition in the cannabis industry could erode market share.
- Changing regulatory landscape could impact the company's operations and profitability.
- Fluctuations in cannabis prices could affect revenue and profit margins.
- Dependence on regulatory approvals for cannabis operations creates uncertainty.
- Economic downturns could reduce demand for cannabis products.
What Are the Growth Opportunities for PCLOF?
- Expansion into New Therapeutic Areas: PharmaCielo has the opportunity to expand its product offerings into new therapeutic areas, such as pain management, anxiety, and sleep disorders. The market for cannabis-based therapies in these areas is growing rapidly, driven by increasing awareness of the potential benefits of cannabis. By developing targeted formulations and conducting clinical trials, PharmaCielo can establish a strong position in these high-growth markets. This expansion could significantly increase revenue streams within the next 3-5 years, contingent on regulatory approvals and market acceptance.
- Geographic Expansion: PharmaCielo can pursue geographic expansion into new markets, particularly in Europe and Latin America, where the regulatory landscape for medicinal cannabis is becoming more favorable. These regions represent significant growth opportunities for the company, as demand for medicinal cannabis products continues to rise. Entering these markets would require strategic partnerships, regulatory compliance, and localized marketing efforts. Successful expansion could double the company's revenue base within 5-7 years.
- Development of Proprietary Formulations: PharmaCielo can invest in the development of proprietary cannabis formulations with enhanced efficacy and bioavailability. By leveraging its expertise in cannabis extraction and processing, the company can create differentiated products that command premium pricing. These formulations could target specific medical conditions and offer improved patient outcomes. The development and commercialization of proprietary formulations could generate substantial revenue growth and improve profit margins within the next 2-3 years.
- Strategic Partnerships and Acquisitions: PharmaCielo can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other companies in the cannabis industry can provide access to new markets, distribution channels, and intellectual property. Acquisitions can also accelerate growth and consolidate market share. These partnerships and acquisitions could lead to significant revenue synergies and cost savings within the next 1-3 years.
- Telemedicine Integration: PharmaCielo's telemedicine software offers a unique growth opportunity by integrating cannabis-based therapies with remote healthcare services. By providing patients with convenient access to medical consultations and cannabis prescriptions, the company can enhance its customer base and generate recurring revenue streams. The telemedicine platform can also be used to collect valuable patient data and improve treatment outcomes. The integration of telemedicine services could increase customer lifetime value and drive revenue growth within the next 1-2 years.
What Are PCLOF's Competitive Advantages?
- Focus on medicinal-grade cannabis provides a differentiated product offering.
- Strategic alliance with AssuredTrans Inc. enhances supply chain capabilities.
- Telemedicine software offers a unique value proposition.
What Does PCLOF Do?
PharmaCielo Ltd. was founded with the vision of becoming a global leader in the cultivation, processing, and supply of medicinal-grade cannabis extracts. The company's core business revolves around producing high-quality tetrahydrocannabinol (THC) and cannabidiol (CBD) extracts and related products for the health and wellness market. PharmaCielo serves a diverse clientele, including health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, primarily in Canada and Colombia. The company also offers telemedicine software, expanding its service offerings beyond cannabis extracts. PharmaCielo's operations include cultivation, extraction, processing, and distribution. The company has established a strategic alliance with AssuredTrans Inc. to enhance its supply chain and distribution capabilities. Headquartered in Toronto, Canada, PharmaCielo is strategically positioned to serve both domestic and international markets. The company's focus on medicinal-grade cannabis differentiates it from competitors primarily focused on recreational cannabis. PharmaCielo's gross margin stands at 29.0%, reflecting its ability to generate revenue from its operations. The company continues to explore opportunities to expand its product line and geographic reach within the evolving cannabis market.
What Products and Services Does PCLOF Offer?
- Cultivates medicinal-grade cannabis.
- Processes cannabis to extract key compounds like THC and CBD.
- Produces medicinal-grade cannabis extracts.
- Supplies cannabis extracts to health and wellness product manufacturers.
- Offers telemedicine software solutions.
- Serves pharmacies and medical clinics with cannabis products.
- Provides cannabis extracts to cosmetic companies.
How Does PCLOF Make Money?
- Cultivation and processing of medicinal cannabis.
- Sale of cannabis extracts to manufacturers and distributors.
- Revenue generation through telemedicine software licensing and services.
What Industry Does PCLOF Operate In?
PharmaCielo Ltd. operates within the rapidly evolving medicinal cannabis industry, which is experiencing significant growth driven by increasing acceptance and legalization of cannabis for medical purposes in various countries. The market is characterized by intense competition, with companies vying for market share in cultivation, extraction, and product development. Key competitors include companies like Aurora Cannabis (AUSAF), Avanti Health Technologies (AVTBF), and others focused on cannabis cultivation and extraction. PharmaCielo's focus on medicinal-grade cannabis and its strategic alliance with AssuredTrans Inc. position it to capitalize on the growing demand for high-quality cannabis extracts.
Who Are PCLOF's Key Customers?
- Health and wellness product manufacturers.
- Pharmacies and medical clinics.
- Cosmetic companies.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 42 |
| 2026-08-26 | 42 |
| 2026-08-29 | 42 |
| 2026-09-01 | 42 |
| 2026-09-04 | 42 |
| 2026-09-07 | 42 |
| 2026-09-10 | 42 |
What changed?
The score has stayed at 42.
Over the same 18 days the stock moved -15.9%.
Company Profile
PharmaCielo Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Marc Lustig. PCLOF has traded publicly since 2019.
PharmaCielo Ltd. Financial Trajectory
PharmaCielo Ltd. (PCLOF) reported $1.0M in revenue for Q2 FY2026, reflecting 93.1% growth compared to the prior quarter. The company recorded a net loss of $1.0M, with diluted EPS of $-0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, PCLOF averaged $-0.00 in diluted EPS.
How PharmaCielo Ltd. Is Valued
PharmaCielo Ltd. carries a market capitalization of $7.04M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for PharmaCielo Ltd. stands at 35.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -32.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
PharmaCielo Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.27 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
PharmaCielo Ltd. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 52.6% below estimates on average.
PCLOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on medicinal-grade cannabis.
- Strategic alliance with AssuredTrans Inc.
- Telemedicine software offering.
- Operations in Canada and Colombia.
Bear Case
- Negative profit margin.
- Limited market share.
- Dependence on regulatory approvals.
- Limited brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$1M | -$0.01 |
| Q1 FY2026 | $519,444.4 | -$938,513.742 | -$0.0047 |
| Q4 FY2025 | $436,723.544 | $293,534.362 | $0.0016 |
| Q3 FY2025 | $641,062.473 | -$1M | -$0.01 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
PCLOF Latest News
-
PharmaCielo Announces 2026 First Quarter Results
newsfilecorp.com · Aug 28, 2026
-
PharmaCielo Announces 2026 Year-End Results
newsfilecorp.com · Jul 30, 2026
-
The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More
· Sep 17, 2021
-
Cannabis Movers & Shakers: Village Farms, Hollister Biosciences, PharmaCielo, Forian, MJardin
· Sep 3, 2021
PCLOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PCLOF.
Price Targets
Wall Street price target analysis for PCLOF.
PCLOF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PCLOF; grades run from A+ (80-100) to F (below 30).
Latest News
PharmaCielo Announces 2026 First Quarter Results
PharmaCielo Announces 2026 Year-End Results
The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More
Cannabis Movers & Shakers: Village Farms, Hollister Biosciences, PharmaCielo, Forian, MJardin
Leadership: Marc Lustig
CEO
Marc Lustig serves as the CEO of PharmaCielo Ltd., leading the company's strategic direction and operations. His background includes experience in the cannabis industry, with a focus on developing and commercializing medicinal cannabis products. He is responsible for overseeing the company's cultivation, processing, and distribution activities, as well as its telemedicine software development. Lustig's leadership is critical to PharmaCielo's efforts to expand its market share and achieve profitability.
Track Record: Under Marc Lustig's leadership, PharmaCielo has focused on expanding its medicinal cannabis product line and establishing strategic partnerships. He has overseen the company's efforts to navigate the complex regulatory landscape and secure necessary approvals for its operations. A key achievement has been the strategic alliance with AssuredTrans Inc., aimed at improving supply chain efficiencies. Lustig's focus remains on driving revenue growth and improving financial performance.
PCLOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PharmaCielo Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is distinct from exchanges like NYSE or NASDAQ, which have stringent listing requirements.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to potential information asymmetry.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- OTC Other tier listing indicates a higher risk of fraud or manipulation.
- Dependence on regulatory approvals for cannabis operations creates uncertainty.
- Negative profit margin raises concerns about financial sustainability.
- Verify the availability and accuracy of financial statements.
- Assess the company's compliance with regulatory requirements.
- Evaluate the company's management team and their track record.
- Analyze the company's business model and competitive positioning.
- Review the company's risk factors and potential liabilities.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Operations in Canada and Colombia suggest a degree of established business activity.
- Strategic alliance with AssuredTrans Inc. indicates potential for supply chain improvements.
- Focus on medicinal-grade cannabis aligns with a growing market segment.
- Telemedicine software offering provides a unique value proposition.
- Presence of a CEO (Marc Lustig) suggests formal leadership structure.
Common Questions About PCLOF (Healthcare)
Is PCLOF a good stock?
Stock Expert AI does not rate PCLOF buy, sell or hold. PharmaCielo Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about PCLOF stock?
Currently, there is no available analyst coverage for PCLOF stock. Given the company's micro-cap status and listing on the OTC Other tier, it may not attract significant analyst attention.
What are the key factors to evaluate for PCLOF?
Evaluate PCLOF on fundamentals, analyst consensus, and risk factors. The company's strategic alliance with AssuredTrans Inc. could improve its supply chain efficiencies and market access. Not financial advice.
How frequently does PCLOF data refresh on this page?
PCLOF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PCLOF's recent stock price performance?
PharmaCielo Ltd. (PCLOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on medicinal-grade cannabis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PCLOF overvalued or undervalued right now?
PharmaCielo Ltd. (PCLOF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PCLOF?
Yes, most major brokerages offer fractional shares of PharmaCielo Ltd. (PCLOF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track PCLOF's earnings and financial reports?
PharmaCielo Ltd. (PCLOF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for PCLOF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.